Health

Patients with EGFR expressing non-small-cell lung cancer benefit most from necitumumab added to chemotherapy

Patients with epidermal growth factor receptor (EGFR) expressing advanced squamous non-small-cell lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the…
Continue Reading
12